Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 10.585 USD -1.17%
Market Cap: 446.7m USD
Have any thoughts about
Urogen Pharma Ltd?
Write Note

Urogen Pharma Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Urogen Pharma Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Urogen Pharma Ltd
NASDAQ:URGN
Total Current Assets
$295.1m
CAGR 3-Years
33%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Total Current Assets
$28m
CAGR 3-Years
70%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Total Current Assets
$164.4m
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
5%
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Total Current Assets
$28.6m
CAGR 3-Years
-32%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Total Current Assets
$7.3m
CAGR 3-Years
-36%
CAGR 5-Years
3%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Total Current Assets
â‚Ş14.6m
CAGR 3-Years
-44%
CAGR 5-Years
55%
CAGR 10-Years
15%
No Stocks Found

Urogen Pharma Ltd
Glance View

Market Cap
446.6m USD
Industry
Biotechnology

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

URGN Intrinsic Value
30.401 USD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is Urogen Pharma Ltd's Total Current Assets?
Total Current Assets
295.1m USD

Based on the financial report for Sep 30, 2024, Urogen Pharma Ltd's Total Current Assets amounts to 295.1m USD.

What is Urogen Pharma Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
13%

Over the last year, the Total Current Assets growth was 62%. The average annual Total Current Assets growth rates for Urogen Pharma Ltd have been 33% over the past three years , 13% over the past five years .

Back to Top